Moderna posts a narrower-than-anticipated loss and sharply higher revenue for the first quarter.

Vertex Pharmaceuticals halted a cystic fibrosis program in the works with Moderna over lung inflammation concerns. The ...

By Julie Steenhuysen, Siddhi Mahatole and Mariam Sunny May 1 (Reuters) - Moderna surpassed Wall Street estimates for ...

The results are part of the company’s strategy to “diversify our geographic footprint” and rely less on the US market, Chief ...

CEO Stéphane Bancel expressed confidence in Moderna’s first quarter, touting the revenue numbers as a sign of the company’s ...

Pfizer (NYSE:PFE | PFE Price Prediction) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is ...

Reports first quarter revenue of $0.4 billion, with approximately 80% of revenue from international marketsReports ...

Moderna jumps despite a Q1 loss as strong international vaccine sales drive revenue surge and boost investor sentiment.

CAMBRIDGE, MA / ACCESS Newswire / August 27, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License ...

A phase 3 study of Moderna’s investigational mRNA-based H5 pandemic influenza vaccine candidate has been initiated. Read more ...

Moderna (MRNA) reports Q1 earnings May 1 premarket—see consensus EPS (-$3.96), revenue ($236M), and estimate revisions to ...

Moderna Inc. said it would ask U.S. and European regulators Monday to allow emergency use of its COVID-19 vaccine as new study results confirm the vaccine offers strong protection — ramping up the ...